European medicines agencies launch public consultation on joint strategy

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have developed a joint strategy for the next five years. It was recently released for a two-month public consultation period (6 July, 2020).

It outlines six priority areas:

• the availability and accessibility of medicines;
• data analytics, digital tools and digital transformation;
• innovation;
• antimicrobial resistance and other emerging health threats;
• supply chain challenges; and
• the sustainability of the network and operational excellence.

The draft strategy details how European agencies can continue to ensure safe supply of medicines and meet patients needs in the face of technological developments and threats including pandemics like COVID-19.

Read the DRAFT STRATEGY here.

Cromos Pharma proudly supports the Right2hope initiative, empowering patients to explore treatment options beyond traditional clinical trials. Through an intuitive, AI-supported matching algorithm, Right2hope connects patients with the most relevant expanded access, compassionate use, and right-to-try programs.